Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials - PubMed
Meta-Analysis
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials
Chantal Quinten et al. Lancet Oncol. 2009 Sep.
Abstract
Background: Although individual studies show that baseline health-related quality of life (HRQOL) is a prognostic factor for survival, contradictory results have been published and very few meta-analyses have confirmed the finding. We examined whether HRQOL scores are associated with survival when pooled across a large sample of patients with different disease sites.
Methods: We selected 30 randomised controlled trials from the European Organisation for Research and Treatment of Cancer (EORTC) started between 1986 and 2004, which included survival data for 10 108 patients with 11 different cancer sites. Patients were eligible for inclusion if they had completed a baseline HRQOL assessment with the EORTC core quality of life questionnaire (QLQ-C30; n=7417). Sociodemographic variables were age (<or=60 vs >60 years) and sex (men vs women), and clinical variables were WHO performance status (0-1 vs 2-3), distant metastases (no vs yes), and cancer site. We assessed prognostic significance of sociodemographic and clinical variables and the 15 QLQ-C30 scales with Cox proportional hazard models.
Findings: In the stratified multivariate model including sociodemographic, clinical, and HRQOL data, the HRQOL parameters of physical functioning (hazard ratio 0.94, 95% CI 0.92-0.96; p<0.0001), pain (1.04, 1.02-1.06; p<0.0001), and appetite loss (1.05, 1.03-1.06; p<0.0001) provided significant prognostic information in addition to the parameters age (1.17, 1.06-1.28; p=0.0001), sex (0.74, 0.67-0.82; p<0.0001), and distant metastases (1.70, 1.49-1.93; p<0.0001), but not for WHO performance status (1.07, 0.97-1.19; p=0.11). Consideration of the three HRQOL parameters and sociodemographic and clinical data increased the predictive accuracy of prognosis of overall survival by 6% relative to sociodemographic and clinical characteristics alone (C statistic for concordance between predicted and observed overall survival 0.68 for sociodemographic and clinical variables, and 0.72 for sociodemographic, clinical, and HRQOL variables).
Interpretation: The results suggest that HRQOL scales provide prognostic information in addition to that of sociodemographic and clinical measures. This study shows that HRQOL data can help to predict survival in patients with cancer.
Funding: Merck KGaA, EORTC Charitable Trust, and National Cancer Institute.
Similar articles
-
Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C, Bjordal K, Greimel E, Reeve BB, Maringwa J, Ediebah DE, Zikos E, King MT, Osoba D, Taphoorn MJ, Flechtner H, Schmucker-Von Koch J, Weis J, Bottomley A; Patient Reported Outcomes and Behavioral Evidence (PROBE) and the European Organization for Research and Treatment of Cancer (EORTC) Clinical Groups. Quinten C, et al. Cancer. 2014 Jan 15;120(2):302-11. doi: 10.1002/cncr.28382. Epub 2013 Oct 11. Cancer. 2014. PMID: 24127333
-
Grande GE, Farquhar MC, Barclay SI, Todd CJ. Grande GE, et al. Palliat Support Care. 2009 Sep;7(3):289-97. doi: 10.1017/S1478951509990216. Palliat Support Care. 2009. PMID: 19788770
-
Meyer F, Fortin A, Gélinas M, Nabid A, Brochet F, Têtu B, Bairati I. Meyer F, et al. J Clin Oncol. 2009 Jun 20;27(18):2970-6. doi: 10.1200/JCO.2008.20.0295. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451440 Clinical Trial.
-
Husson O, de Rooij BH, Kieffer J, Oerlemans S, Mols F, Aaronson NK, van der Graaf WTA, van de Poll-Franse LV. Husson O, et al. Oncologist. 2020 Apr;25(4):e722-e732. doi: 10.1634/theoncologist.2019-0348. Epub 2019 Oct 31. Oncologist. 2020. PMID: 32297435 Free PMC article. Review.
-
Luckett T, Goldstein D, Butow PN, Gebski V, Aldridge LJ, McGrane J, Ng W, King MT. Luckett T, et al. Lancet Oncol. 2011 Dec;12(13):1240-8. doi: 10.1016/S1470-2045(11)70212-1. Epub 2011 Oct 11. Lancet Oncol. 2011. PMID: 21996168 Review.
Cited by
-
Baude J, Guigou C, Thibouw D, Vulquin N, Folia M, Constantin G, Boustani J, Duvillard C, Ladoire S, Truc G, Bertaut A, Chevalier C. Baude J, et al. PLoS One. 2024 Jul 25;19(7):e0307658. doi: 10.1371/journal.pone.0307658. eCollection 2024. PLoS One. 2024. PMID: 39052674 Free PMC article.
-
Goto Y, Yoh K, Kato T, Hosomi Y, Usui K, Fukui T, Hirano K, Tanaka H, Taguri M, Kunitoh H. Goto Y, et al. Jpn J Clin Oncol. 2023 Jan 28;53(2):153-160. doi: 10.1093/jjco/hyac159. Jpn J Clin Oncol. 2023. PMID: 36300307 Free PMC article.
-
Eser S, Göksel T, Erbaycu AE, Baydur H, Başarık B, Yanık AÖ, Gürsul KK, Çelik P, Ediz EÇ, Hatipoğlu O, Yayla BA, Başer S, Eser E. Eser S, et al. Springerplus. 2016 Oct 21;5(1):1833. doi: 10.1186/s40064-016-3492-7. eCollection 2016. Springerplus. 2016. PMID: 27818871 Free PMC article.
-
Leo S, Arnoldi E, Repetto L, Coccorullo Z, Cinieri S, Fedele P, Cazzaniga M, Lorusso V, Latorre A, Campanella G, Ciccarese M, Accettura C, Pisconti S, Rinaldi A, Brunetti C, Raffaele M, Coltelli L, Spazzapan S, Fratino L, Petrucelli L, Biganzoli L. Leo S, et al. Oncologist. 2019 Jun;24(6):e232-e240. doi: 10.1634/theoncologist.2017-0676. Epub 2018 Nov 9. Oncologist. 2019. PMID: 30413667 Free PMC article.
-
Hall RK, Luciano A, Pieper C, Colón-Emeric CS. Hall RK, et al. BMC Nephrol. 2018 Jan 15;19(1):11. doi: 10.1186/s12882-017-0801-5. BMC Nephrol. 2018. PMID: 29334904 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources